West Pharma Insiders Exercise $534K in Stock Options Amid Tax Payments
West Pharmaceutical Services (NYSE: WST) saw concentrated insider trading activity this week, with five executives conducting 14 transactions totaling $534,610 between February 16-23, 2026. The activity primarily consisted of stock option exercises followed by shares sold to cover tax obligations, a common pattern during restricted stock vesting periods.
The Trades
The trading cluster centered around February 17-18, when multiple executives received stock awards and immediately sold shares to cover tax withholdings. CEO Eric Mark Green led the activity with the largest transactions, selling 1,878.933 shares worth $459,845 to cover taxes on newly vested equity compensation.
CFO Robert W. McMahon executed the second-largest transaction earlier in the month, exercising 4,230.525 shares on February 11 and selling 1,250.034 shares at $246.16 per share to cover $307,708 in tax obligations.
The remaining executives — including SVP Rodolphe Jean Poussot, VP Charles Witherspoon, and Chief Accounting Officer Chad Winters — conducted similar but smaller transactions, each selling shares worth between $6,900 and $45,400 to meet tax requirements.
All tax payment sales occurred at prices between $243.19 and $248.26 per share, reflecting West Pharmaceutical's current trading range. The timing appears coordinated around a February 17 vesting date for multiple restricted stock awards.
Who's Trading
The insider group represents West Pharmaceutical's core leadership team across operations, finance, and strategy:
Eric Mark Green (President, CEO, and Board Chair) accounted for the majority of activity with $459,845 in tax-related sales across two days. Green exercised 1,318.81 shares on February 18 while selling 1,878.933 shares total to cover taxes.
Robert W. McMahon (Senior VP and CFO) was awarded 12,670 shares in August 2025 and exercised 4,230.525 shares in February, selling approximately 30% to cover $307,708 in taxes.
Annette F. Favorite (Senior VP and Chief HR Officer) sold 186.2 shares for $45,463 in tax payments after exercising 135.491 shares.
Chad Winters (VP and Chief Accounting Officer) and Charles Witherspoon (VP and Treasurer) each sold modest amounts — $12,300 and $10,097 respectively — following restricted stock awards.
The transactions also included small quarterly dividend reinvestment purchases by board member Janet Brutschea Haugen totaling $25,248 in Q3 and Q4 2025.
What to Watch
This trading pattern suggests routine compensation-related activity rather than discretionary buying or selling. The synchronized February 17 vesting date and immediate tax withholding sales indicate these were scheduled transactions tied to equity compensation plans, not market-timing decisions by insiders.
The absence of open-market purchases or discretionary sales is notable. All major transactions were either option exercises or mandatory tax withholdings, suggesting insiders are neither aggressively accumulating nor divesting their holdings.
West Pharmaceutical Services, a $7.5 billion market cap supplier of drug packaging and delivery systems, has seen its stock trade between $240-280 over the past quarter. The tax payment sales at $243-248 per share occurred near the lower end of this range.
For context, insider ownership remains substantial despite these tax-related sales. CEO Green retained the majority of his exercised shares after covering taxes, as did other executives. The pattern of exercising options while selling only enough to cover taxes typically signals confidence in longer-term prospects.
Investors should monitor whether insiders begin discretionary buying if the stock remains near current levels, or whether additional tax-related selling emerges as more restricted stock vests in coming quarters. The next major vesting window will likely provide clearer signals about insider sentiment toward West Pharmaceutical's valuation.
*Source: SEC Form 4 filings dated February 2026*
*StockCliff Research*